Zenagamtide and CagriSema are different experimental treatments. Both are being studied for weight and blood-sugar outcomes through GLP-1 and amylin signaling. Zenagamtide (formerly called amycretin) is one engineered molecule. CagriSema combines two molecules: cagrilintide and semaglutide. Similar targets do not make their trial results, formulations, or amounts interchangeable.
The difference in one glance
- Zenagamtide: one molecule designed to activate GLP-1 and amylin receptors. Researchers have studied an injected, once-weekly version and a separate oral version. Read the injected phase 2 trial.
- CagriSema: a fixed combination of cagrilintide, an amylin-receptor agonist, and semaglutide, a GLP-1-receptor agonist. Read the REDEFINE 1 phase 3 trial.
Why are people interested?
The two hormone pathways are involved in appetite and blood-sugar regulation. Researchers are testing whether targeting both can improve outcomes in obesity or type 2 diabetes. This is a reason for research, not a promise that a vial sold online produces the same effect. Novo Nordisk describes zenagamtide and CagriSema as investigational products.
What does human research actually show?
Zenagamtide: human clinical evidence, still developing. A randomized, placebo-controlled phase 2 study tested the injected form in adults with type 2 diabetes. The study reported blood-sugar and weight findings over 36 weeks. Phase 2 helps researchers choose what to test next; it does not establish the results or long-term safety expected from a completed phase 3 program. There is also an oral zenagamtide phase 2 study. The oral and injected forms should not be treated as the same product.
CagriSema: phase 3 human clinical evidence. In the published REDEFINE 1 trial, adults with obesity or overweight and a related condition, but without type 2 diabetes, were studied for 68 weeks. Estimated average weight change was 20.4% with CagriSema and 3.0% with placebo. That is a result for the trial product, population, and protocol. It does not verify an online research vial or predict any one person’s outcome. See the original study.
Can the trial numbers be compared directly?
No. These are different molecules studied in different groups for different lengths of time. Comparing their percentages side by side would not tell us which works better. The trials cited here did not assign participants to zenagamtide versus CagriSema in the same study.
There is also a label-reading trap: a CagriSema trial amount written as two numbers describes two ingredients. A zenagamtide amount describes one molecule. You cannot convert one into the other using vial math. Our cagrilintide and CagriSema guide explains those names in more detail.
What about online vials and reported use?
Neither a trial schedule nor a discussion-board amount establishes a protocol for a purchased research vial. The reviewed clinical sources do not establish a community-reported amount, frequency, route, or cycle that we could responsibly present as typical for either online product. Before even comparing a seller’s claim with a paper, check which ingredients and batch a lab report actually names. Our COA guide walks through that check; JD BioWorks’ field-by-field COA article provides additional context on matching the report to the named material. A matching document alone does not prove the vial is suitable for human use.
Plain answer: same two research pathways, different products and different evidence. As of October 7, 2026, Novo Nordisk still describes both as investigational. Read the trial name, ingredients, study population, and evidence level before treating a number online as meaningful.